制吐剤の市場規模、シェア、動向分析レポート:薬剤タイプ別(セロトニン受容体拮抗薬、ドパミン受容体拮抗薬)、用途別、最終用途別、地域別、セグメント別予測、2024年~2030年Antiemetics Drugs Market Size, Share & Trends Analysis Report By Drug Type (Serotonin-receptor Antagonists, Dopamine Receptor Antagonists), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030 制吐剤市場の成長と動向 Grand View Research, Inc.の最新レポートによると、制吐剤の世界市場規模は、2024年から2030年にかけて年平均成長率5.98%を示し、2030年までに112億米ドルに達する見込みです。吐き気... もっと見る
1~3営業日
サマリー制吐剤市場の成長と動向Grand View Research, Inc.の最新レポートによると、制吐剤の世界市場規模は、2024年から2030年にかけて年平均成長率5.98%を示し、2030年までに112億米ドルに達する見込みです。吐き気や嘔吐を引き起こす様々な疾患の有病率の増加と相まって、主要企業の戦略的イニシアチブの増加などの要因が、市場の需要を促進している。 主要な業界プレイヤーの活動の高まりは、制吐剤の需要を強化する主な要因の1つです。業界参加者は、制吐剤市場での地位を強化するために、提携、買収、新製品の発売、製品の承認、事業拡大など様々な取り組みを行っている。例えば、2020年5月、米国食品医薬品局は、化学療法によって誘発される吐き気と嘔吐の予防を目的としたヘルシン・グループのAKYNZEO注射剤を承認した。このように、新規製品の承認の増加は、今後数年間の業界の成長を促進すると予想される。 化学療法や術後の悪心・嘔吐(PONV)といった主な適応症に加え、食中毒や飲酒といった他の症状も、予測期間中、これらの医薬品の需要を牽引している。NCBIが2021年11月に発表した論文によると、サブサリチル酸ビスマスなどの特定の市販制吐薬は、食中毒に伴う吐き気や嘔吐に有効であることが示唆されている。 さらに、2022年10月にFrontiers誌に掲載された研究では、セロトニン受容体拮抗薬であるオンダンセトロンが、早期発症アルコール依存症(EOA)患者におけるアルコール使用障害に有効な治療薬であることが報告された。その結果、制吐薬の需要は、アルコール消費の増加や食中毒の発生に対応して増加すると予想される。 制吐薬市場レポートハイライト - 薬剤の種類別では、セロトニン受容体拮抗薬セグメントが2023年に29.71%で市場を支配しており、この優位性は、セロトニン受容体拮抗薬の使用の増加と相まって癌の症例が増加していることに起因している。 - 用途別では、化学療法に伴う悪心・嘔吐をターゲットとした製品の上市が増加していることから、化学療法分野が2023年に45.70%のシェアを占め、市場最大の収益貢献者となった。 - 最終用途セグメントでは、小売薬局セグメントが2023年に47.91%の収益シェアで市場を支配した。対照的に、その他のセグメントは予測期間中に最速の成長を記録すると予測されている。 - 北米地域は、Pfizer、Merck Co & Inc、GSK plcのような大手企業の存在により、2023年に36.52%のシェアで市場を支配した。一方、アジア太平洋地域は予測期間中に最も速い成長を示すと予想される。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Segment Definitions 1.1.1. Drug Type Segment 1.1.2. Application Segment 1.1.3. End-use Segment 1.2. Regional Scope 1.3. Estimates and Forecast Timeline 1.4. Objectives 1.4.1. Objective - 1 1.4.2. Objective - 2 1.4.3. Objective - 3 1.5. Research Methodology 1.6. Information Procurement 1.6.1. Purchased Database 1.6.2. GVR’s Internal Database 1.6.3. Secondary Sources 1.6.4. Primary Research 1.7. Information or Data Analysis 1.7.1. Data Analysis Models 1.8. Market Formulation & Validation 1.9. Model Details 1.9.1. Commodity Flow Analysis 1.10. List of Secondary Sources 1.11. List of Abbreviations 1.12. Research Assumptions Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Segment Snapshot 2.3. Competitive Landscape Snapshot Chapter 3. Market Variables, Trends, & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Increasing Prevalence of Target Diseases 3.2.1.2. Rising Investments by Industry Participants in R&D Activities 3.2.2. Market Restraint Analysis 3.2.2.1. Adverse Effects Associated with Anti emetics Drugs 3.3. Industry Analysis Tools 3.3.1. Porter’s Five Forces Analysis 3.3.2. PESTEL Analysis 3.3.3. COVID-19 Impact Analysis Chapter 4. Drug Type Business Analysis 4.1. Antiemetics Drugs Market: Drug Type Movement Analysis 4.2. Serotonin-Receptor Antagonists 4.2.1. Serotonin-Receptor Antagonists Market, 2018 - 2030 (USD Million) 4.3. Anticholinergics 4.3.1. Anticholinergics Market, 2018 - 2030 (USD Million) 4.4. Dopamine Receptor Antagonists 4.4.1. Dopamine Receptor Antagonists Market, 2018 - 2030 (USD Million) 4.5. Neurokinin Receptor Antagonists 4.5.1. Neurokinin Receptor Antagonists Market, 2018 - 2030 (USD Million) 4.6. Others 4.6.1. Other Drug Types Market, 2018 - 2030 (USD Million) Chapter 5. Application Business Analysis 5.1. Antiemetics Drugs Market: Application Movement Analysis 5.2. Chemotherapy 5.2.1. Chemotherapy Market, 2018 - 2030 (USD Million) 5.3. Gastroenteritis 5.3.1. Gastroenteritis Market, 2018 - 2030 (USD Million) 5.4. Post-Operative Surgery 5.4.1. Post Operative Surgery Market, 2018 - 2030 (USD Million) 5.5. Others 5.5.1. Others Market, 2018 - 2030 (USD Million) Chapter 6. End-use Business Analysis 6.1. Antiemetics Drugs Market: End-use Movement Analysis 6.2. Hospital & Clinics 6.2.1. Hospital & Clinics Market, 2018 - 2030 (USD Million) 6.3. Retail Pharmacy 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million) 6.4. Others 6.4.1. Other End-use Market, 2018 - 2030 (USD Million) Chapter 7. Regional Business Analysis 7.1. Antiemetics Drugs Market Share By Region, 2023 & 2030 7.2. North America 7.2.1. North America Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Regulatory Framework 7.2.2.4. U.S. Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Regulatory Framework 7.2.3.4. Canada Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.2. UK 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Regulatory Framework 7.3.2.4. UK Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.3. Germany 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Regulatory Framework 7.3.3.4. Germany Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.4. France 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Regulatory Framework 7.3.4.4. France Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.5. Italy 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Regulatory Framework 7.3.5.4. Italy Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.6. Spain 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Regulatory Framework 7.3.6.4. Spain Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Regulatory Framework 7.3.7.4. Denmark Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Regulatory Framework 7.3.8.4. Sweden Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Regulatory Framework 7.3.9.4. Norway Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia Pacific Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. Japan Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. China Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Regulatory Framework 7.4.4.4. India Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.5. Australia 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Regulatory Framework 7.4.5.4. Australia Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.6. Thailand 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Regulatory Framework 7.4.6.4. Thailand Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.7. South Korea 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Regulatory Framework 7.4.7.4. South Korea Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Brazil Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. Mexico Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. Argentina Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6. MEA 7.6.1. MEA Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. South Africa Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. Saudi Arabia Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. UAE Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Kuwait Antiemetics Drugs Market, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Strategy Mapping 8.3. Company Market Share Analysis, 2023 8.4. Company Profiles/Listing 8.4.1. Pfizer Inc. 8.4.1.1. Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. Cipla Inc. 8.4.2.1. Overview 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.2.3. Product Benchmarking 8.4.2.4. Strategic Initiatives 8.4.3. Merck KGaA 8.4.3.1. Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. Eagle Pharmaceuticals, Inc. 8.4.4.1. Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. Johnson & Johnson Services, Inc. 8.4.5.1. Overview 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.5.3. Product Benchmarking 8.4.5.4. Strategic Initiatives 8.4.6. GSK plc. 8.4.6.1. Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. Astellas Pharma Inc. 8.4.7.1. Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. GLENMARK PHARMACEUTICALS LTD. 8.4.8.1. Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. Viatris Inc. 8.4.9.1. Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. Baxter 8.4.10.1. Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives
SummaryAntiemetics Drugs Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Segment Definitions 1.1.1. Drug Type Segment 1.1.2. Application Segment 1.1.3. End-use Segment 1.2. Regional Scope 1.3. Estimates and Forecast Timeline 1.4. Objectives 1.4.1. Objective - 1 1.4.2. Objective - 2 1.4.3. Objective - 3 1.5. Research Methodology 1.6. Information Procurement 1.6.1. Purchased Database 1.6.2. GVR’s Internal Database 1.6.3. Secondary Sources 1.6.4. Primary Research 1.7. Information or Data Analysis 1.7.1. Data Analysis Models 1.8. Market Formulation & Validation 1.9. Model Details 1.9.1. Commodity Flow Analysis 1.10. List of Secondary Sources 1.11. List of Abbreviations 1.12. Research Assumptions Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Segment Snapshot 2.3. Competitive Landscape Snapshot Chapter 3. Market Variables, Trends, & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Increasing Prevalence of Target Diseases 3.2.1.2. Rising Investments by Industry Participants in R&D Activities 3.2.2. Market Restraint Analysis 3.2.2.1. Adverse Effects Associated with Anti emetics Drugs 3.3. Industry Analysis Tools 3.3.1. Porter’s Five Forces Analysis 3.3.2. PESTEL Analysis 3.3.3. COVID-19 Impact Analysis Chapter 4. Drug Type Business Analysis 4.1. Antiemetics Drugs Market: Drug Type Movement Analysis 4.2. Serotonin-Receptor Antagonists 4.2.1. Serotonin-Receptor Antagonists Market, 2018 - 2030 (USD Million) 4.3. Anticholinergics 4.3.1. Anticholinergics Market, 2018 - 2030 (USD Million) 4.4. Dopamine Receptor Antagonists 4.4.1. Dopamine Receptor Antagonists Market, 2018 - 2030 (USD Million) 4.5. Neurokinin Receptor Antagonists 4.5.1. Neurokinin Receptor Antagonists Market, 2018 - 2030 (USD Million) 4.6. Others 4.6.1. Other Drug Types Market, 2018 - 2030 (USD Million) Chapter 5. Application Business Analysis 5.1. Antiemetics Drugs Market: Application Movement Analysis 5.2. Chemotherapy 5.2.1. Chemotherapy Market, 2018 - 2030 (USD Million) 5.3. Gastroenteritis 5.3.1. Gastroenteritis Market, 2018 - 2030 (USD Million) 5.4. Post-Operative Surgery 5.4.1. Post Operative Surgery Market, 2018 - 2030 (USD Million) 5.5. Others 5.5.1. Others Market, 2018 - 2030 (USD Million) Chapter 6. End-use Business Analysis 6.1. Antiemetics Drugs Market: End-use Movement Analysis 6.2. Hospital & Clinics 6.2.1. Hospital & Clinics Market, 2018 - 2030 (USD Million) 6.3. Retail Pharmacy 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million) 6.4. Others 6.4.1. Other End-use Market, 2018 - 2030 (USD Million) Chapter 7. Regional Business Analysis 7.1. Antiemetics Drugs Market Share By Region, 2023 & 2030 7.2. North America 7.2.1. North America Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Regulatory Framework 7.2.2.4. U.S. Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Regulatory Framework 7.2.3.4. Canada Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.2. UK 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Regulatory Framework 7.3.2.4. UK Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.3. Germany 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Regulatory Framework 7.3.3.4. Germany Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.4. France 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Regulatory Framework 7.3.4.4. France Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.5. Italy 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Regulatory Framework 7.3.5.4. Italy Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.6. Spain 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Regulatory Framework 7.3.6.4. Spain Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Regulatory Framework 7.3.7.4. Denmark Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Regulatory Framework 7.3.8.4. Sweden Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Regulatory Framework 7.3.9.4. Norway Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia Pacific Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. Japan Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. China Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Regulatory Framework 7.4.4.4. India Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.5. Australia 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Regulatory Framework 7.4.5.4. Australia Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.6. Thailand 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Regulatory Framework 7.4.6.4. Thailand Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.4.7. South Korea 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Regulatory Framework 7.4.7.4. South Korea Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Brazil Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. Mexico Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. Argentina Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6. MEA 7.6.1. MEA Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. South Africa Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. Saudi Arabia Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. UAE Antiemetics Drugs Market, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Kuwait Antiemetics Drugs Market, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Strategy Mapping 8.3. Company Market Share Analysis, 2023 8.4. Company Profiles/Listing 8.4.1. Pfizer Inc. 8.4.1.1. Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. Cipla Inc. 8.4.2.1. Overview 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.2.3. Product Benchmarking 8.4.2.4. Strategic Initiatives 8.4.3. Merck KGaA 8.4.3.1. Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. Eagle Pharmaceuticals, Inc. 8.4.4.1. Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. Johnson & Johnson Services, Inc. 8.4.5.1. Overview 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.5.3. Product Benchmarking 8.4.5.4. Strategic Initiatives 8.4.6. GSK plc. 8.4.6.1. Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. Astellas Pharma Inc. 8.4.7.1. Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. GLENMARK PHARMACEUTICALS LTD. 8.4.8.1. Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. Viatris Inc. 8.4.9.1. Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. Baxter 8.4.10.1. Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(中枢神経系作用薬)の最新刊レポート
Grand View Research 社の最新刊レポート
本レポートと同じKEY WORD(dopamine receptor)の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/05 10:26 153.43 円 167.28 円 201.52 円 |